China AI: Bernstein sees chipmakers benefiting from Nvidia scrutiny
On Monday, H.C. Wainwright reiterated its Buy rating and $20.00 price target for Kalvista Pharmaceuticals Inc (NASDAQ:KALV), ahead of the company’s anticipated PDUFA date on June 17, 2025. The stock has shown strong momentum, gaining nearly 49% year-to-date, with analyst targets ranging from $18 to $39. According to InvestingPro data, the company maintains a strong analyst consensus rating of 1.3 (Strong Buy). Analysts at the firm highlighted the potential of Kalvista’s sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE), which is expected to launch shortly after the PDUFA date.
The optimism for sebetralstat stems from its ease of use compared to current on-demand treatments that require parenteral administration, often leading to delays or withholding of therapy. This was underscored by a study published in the New England Journal of Medicine in 2024, which detailed the need for on-demand treatments for HAE patients, even those on prophylactic therapies.
Analysts noted that despite advancements in prophylactic treatments for HAE, patients still need on-demand therapies, as nearly half of those on prophylactics continue to experience attacks. InvestingPro analysis shows the company maintains a healthy financial position with more cash than debt and a strong current ratio of 10.44, providing adequate resources for the drug’s launch. The severity of breakthrough attacks on prophylactic therapy is similar to those experienced by patients relying solely on on-demand therapy, contradicting the belief that such attacks are less severe.
The demand for on-demand treatments remains robust, as evidenced by the stable total volume of on-demand therapy usage, despite the introduction of new prophylactics. Sebetralstat is seen as a potentially strong competitor in the market due to its non-invasive administration and effectiveness.
The firm’s analysts concluded that the anticipated launch of sebetralstat could reflect a strong demand for the product, given its advantages over existing therapies. They reaffirmed their Buy rating and $20 price target for Kalvista Pharmaceuticals Inc, expressing confidence in the drug’s market potential. With a market capitalization of $626 million and six analysts recently revising earnings estimates upward, the company shows promising signs. Discover more valuable insights and 10 additional ProTips for KALV with InvestingPro.
In other recent news, Kalvista Pharmaceuticals Inc. has been actively advancing its investigational drug, sebetralstat, as a potential oral on-demand treatment for hereditary angioedema (HAE). At the AAAAI/WAO 2025 Joint Congress, the company shared promising data from the KONFIDENT-S study, highlighting sebetralstat’s potential to significantly reduce the time to relief for HAE attacks. The drug is currently under regulatory review by the U.S. FDA, with a PDUFA goal date set for June 17, 2025. Analysts from Jefferies have adjusted Kalvista’s price target to $31, while maintaining a ’Buy’ rating, reflecting confidence in the market opportunity for sebetralstat. JMP Securities also reiterated a Market Outperform rating for Kalvista, with a price target of $19, citing the drug’s potential to expand the on-demand treatment market for HAE. Their analysts highlighted that more than 15% of HAE patients favor on-demand treatments, and a survey indicated that two-thirds of doctors believe an oral option would lead to more frequent treatment of attacks. Kalvista is scheduled to provide further insights into its commercial strategy during a virtual Investor Day event on March 25. These developments are being closely monitored as the company progresses toward the commercial phase of its lead product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.